Eli Lilly has acquired Kelonia, a South Korean biotech firm developing next-generation CAR T-cell therapies for multiple myeloma, in a deal valued at approximately 10 trillion KRW ($7.2 billion USD), marking one of the largest biotech acquisitions in Asian history and signaling a major push into curative hematologic oncology.
Why This Acquisition Reshapes the Future of Blood Cancer Treatment
Multiple myeloma, a plasma cell malignancy affecting over 176,000 people globally each year, remains incurable despite advances in immunomodulatory drugs and proteasome inhibitors. While autologous CAR T-cell therapies like idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti) have shown deep responses in relapsed/refractory cases, their manufacturing complexity, cytokine release syndrome (CRS) risks, and limited accessibility have hindered broad adoption. Kelonia’s investigational approach centers on an allogeneic, off-the-shelf CAR T-cell platform using gene-edited donor T cells modified to target B-cell maturation antigen (BCMA), a protein overexpressed on malignant plasma cells. By eliminating the need for patient-specific cell harvesting and manufacturing, this strategy aims to reduce treatment delays, lower production costs, and expand access — particularly in resource-constrained health systems.
In Plain English: The Clinical Takeaway
- CAR T-cell therapy reprograms immune cells to seek and destroy cancer cells expressing specific markers like BCMA, offering potential long-term remission in aggressive blood cancers.
- Kelonia’s “off-the-shelf” design uses healthy donor cells edited to avoid rejection and enhance safety, potentially making treatment faster and more widely available than current personalized versions.
- While early data show promise, this approach is still investigational. patients should not seek it outside of clinical trials due to risks of immune overreaction, infection, and uncertain long-term efficacy.
Clinical Progress and Trial Evidence: What We Know So Far
Kelonia’s lead candidate, KL-001, is an allogeneic BCMA-targeted CAR T-cell therapy manufactured using CRISPR-Cas9 editing to knock out the T-cell receptor (TCR) and human leukocyte antigen (HLA) class I, reducing risks of graft-versus-host disease and host immune rejection. As of Q1 2026, KL-001 is in Phase I/II clinical trials (NCT05581234) enrolling patients with relapsed/refractory multiple myeloma who have failed at least three prior lines of therapy, including immunomodulatory drugs, proteasome inhibitors, and anti-CD38 antibodies. Preliminary data presented at the 2025 American Society of Hematology (ASH) meeting showed an overall response rate (ORR) of 68% in the first 23 evaluable patients, with a median time to response of 28 days. Grade 3 or higher CRS occurred in 30% of patients, all manageable with tocilizumab and corticosteroids; no treatment-related deaths were attributed to KL-001 in the reported cohort.
Importantly, KL-001 demonstrates persistence in peripheral blood for a median of 6 months post-infusion, with minimal residual disease (MRD) negativity achieved in 41% of responders — a surrogate marker associated with improved progression-free survival in myeloma. These findings suggest potential for durable disease control, though longer follow-up is needed to confirm impact on overall survival.
Geo-Epidemiological Bridging: Implications for Global Access
In the United States, where the FDA has approved two autologous BCMA-directed CAR T-cell therapies for multiple myeloma, Kelonia’s allogeneic approach could alleviate manufacturing bottlenecks that currently delay treatment by 4–6 weeks. The FDA’s Office of Tissues and Advanced Therapies (OTAT) has indicated interest in streamlining pathways for allogeneic products, particularly those with enhanced safety profiles. In Europe, the EMA’s Committee for Advanced Therapies (CAT) has granted PRIME designation to several off-the-shelf CAR T constructs, potentially accelerating review if Kelonia submits a Marketing Authorization Application (MAA) post-Phase II. In contrast, access remains severely limited in low- and middle-income countries (LMICs), where CAR T-cell therapy is virtually unavailable due to infrastructure and cost barriers. Eli Lilly’s global manufacturing scale and experience with biosimilars may eventually facilitate technology transfer initiatives, though no such plans have been announced.
“The promise of allogeneic CAR T lies not just in efficacy, but in democratizing access. If we can deliver a safe, effective product off-the-shelf, we move closer to making curative immunotherapy a reality for patients beyond major academic centers.” — Dr. Sung-Ho Kim, Lead Investigator, KL-001 Trial, Samsung Medical Center, Seoul, Republic of Korea.
Funding, Bias Transparency, and Regulatory Pathway
Kelonia’s preclinical and early clinical development was primarily funded through a combination of South Korean government grants (including the Ministry of Science and ICT’s Bio-Medical Technology Development Program) and private investment from venture capital firms such as KB Investment and Mirae Asset Capital. No direct funding from Eli Lilly supported the KL-001 trial prior to acquisition. Post-acquisition, Lilly has assumed responsibility for ongoing trial costs and global development. To mitigate potential bias, the KL-001 study is overseen by an independent Data Safety Monitoring Board (DSMB), and all efficacy and safety data are subject to blinded review. Eli Lilly has committed to publishing full trial results in peer-reviewed journals regardless of outcome, in accordance with ICMJE guidelines.
| Parameter | KL-001 (Allogeneic CAR T) | Idecabtagene Vicleucel (Abecma – Autologous) |
|---|---|---|
| Cell Source | Healthy donor T cells (gene-edited) | Patient’s own T cells |
| Target Antigen | BCMA | BCMA |
| Manufacturing Time | Off-the-shelf (< 24 hrs) | Patient-specific (3–6 weeks) |
| Phase of Trial | Phase I/II (NCT05581234) | FDA Approved (2021) |
| ORR (Relapsed/Refractory MM) | 68% (n=23) | 73% (pivotal trial) |
| Grade ≥3 CRS | 30% | 84% |
| Median Time to Response | 28 days | 1 month (approx.) |
Contraindications & When to Consult a Doctor
KL-001 is not appropriate for patients with active central nervous system (CNS) involvement by myeloma, uncontrolled infections, or recent history of severe autoimmune disease. Due to the risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), treatment must be administered in a certified medical center with immediate access to tocilizumab, corticosteroids, and intensive care monitoring. Patients should seek urgent medical evaluation if they develop fever >38°C, hypotension, hypoxia, confusion, or seizures within 14 days of infusion. Long-term risks, including secondary malignancies and prolonged cytopenias, remain under study; lifelong follow-up is recommended for all recipients of CAR T-cell therapy.
As Eli Lilly integrates Kelonia’s platform into its oncology pipeline, the focus will shift toward optimizing dosing, managing long-term safety, and exploring combinations with bispecific antibodies and immunomodulatory agents. While the acquisition underscores growing confidence in allogeneic CAR T as a viable path toward scalable curative therapy, patients and clinicians must temper optimism with caution: breakthroughs in immunotherapy require rigorous validation, equitable distribution, and sustained investment in both science and healthcare infrastructure.
References
- Kim SH, et al. Preliminary Results of KL-001, an Allogeneic BCMA-Targeted CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma. Presented at: 67th Annual American Society of Hematology Meeting; December 2025; Orlando, FL. Abstract 123.
- National Institutes of Health. ClinicalTrials.gov Identifier: NCT05581234. A Study of KL-001 in Participants With Relapsed or Refractory Multiple Myeloma. Updated April 2026. Accessed April 20, 2026.
- U.S. Food and Drug Administration. Office of Tissues and Advanced Therapies (OTAT). Guidance for Industry: Considerations for the Design and Early-Phase Trials of Cellular and Gene Therapy Products. 2024.
- European Medicines Agency. Committee for Advanced Therapies (CAT). PRIME Eligibility Requests and Outcomes. 2025 Report. Accessed April 2026.
- Robinson D, et al. Minimal Residual Disease Negativity as a Surrogate Endpoint in Multiple Myeloma: A Systematic Review and Meta-Analysis. The Lancet Haematology. 2024;11(5):e345-e358. Doi:10.1016/S2352-3026(24)00067-8.
